These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 12041769)

  • 1. Imipenem use in serious childhood infections.
    Pavesio D; Pecco P; Giacchino M; Dotti M
    J Chemother; 1991 Jan; 3 Suppl 1():218-21. PubMed ID: 12041769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imipenem/cilastatin therapy of serious infections: a U.S. multicenter noncomparative trial.
    Calandra GB; Hesney M; Brown KR
    Clin Ther; 1985; 7(2):225-38. PubMed ID: 3886144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imipenem-cilastatin in the treatment of hospital infections.
    Mao P; Enrichens F; Olivero G; Sciascia C; Benedetto G; Franchello A; Olivero S
    J Chemother; 1991 Jan; 3 Suppl 1():205-7. PubMed ID: 12041766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of ceftazidime in the treatment of 80 infectious episodes in compromised children.
    Viscoli C; Gargani G; Facco F; Mantero E; Tuo P; Giacchino R; Campelli A; Nantron M; Perlino G
    Int J Clin Pharmacol Ther Toxicol; 1985 Nov; 23(11):629-34. PubMed ID: 3908333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imipenem/cilastatin as empirical treatment of severe infections in compromised patients.
    Biglino A; Bonasso M; Gioannini P
    J Chemother; 1991 Jan; 3 Suppl 1():208-12. PubMed ID: 12041767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic and clinical evaluation of serious infections in premature and newborn infants under therapy with imipenem/cilastatin.
    Böswald M; Döbig C; Kändler C; Krüger C; Scharf J; Soergel F; Zink S; Guggenbichler JP
    Infection; 1999; 27(4-5):299-304. PubMed ID: 10885853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immediate vs. delayed imipenem treatment in cancer patients with profound neutropenia induced by high-dose chemotherapy: results of a randomized study.
    García-Sáenz JA; Martín M; Casado A; Pérez-Segura P; Manrique I; Flores L; Macias JA; Cámara JC; Perezagua C; Díaz-Rubio E
    Rev Esp Quimioter; 2002 Sep; 15(3):257-63. PubMed ID: 12582429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imipenem in acute lung infections and bacterial re-exacerbations of chronic obstructive lung disease.
    Pozzi E; De Rose V
    J Chemother; 1991 Jan; 3 Suppl 1():213-7. PubMed ID: 12041768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized prospective study of cefepime plus metronidazole with imipenem-cilastatin in the treatment of intra-abdominal infections.
    Garbino J; Villiger P; Caviezel A; Matulionyte R; Uckay I; Morel P; Lew D
    Infection; 2007 Jun; 35(3):161-6. PubMed ID: 17565457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime.
    Raad II; Escalante C; Hachem RY; Hanna HA; Husni R; Afif C; Boktour MR; Whimbey EE; Kontoyiannis D; Jacobson K; Kantarjian H; Levett LM; Rolston KV
    Cancer; 2003 Sep; 98(5):1039-47. PubMed ID: 12942573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies.
    Cherif H; Björkholm M; Engervall P; Johansson P; Ljungman P; Hast R; Kalin M
    Scand J Infect Dis; 2004; 36(8):593-600. PubMed ID: 15370671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meropenem.
    Shah D; Narang M
    Indian Pediatr; 2005 May; 42(5):443-50. PubMed ID: 15923690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experience with cefepime versus meropenem as empiric monotherapy for neutropenia and fever in pediatric patients with solid tumors.
    Oguz A; Karadeniz C; Citak EC; Cil V; Eldes N
    Pediatr Hematol Oncol; 2006; 23(3):245-53. PubMed ID: 16517540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on the efficacy and tolerability of meropenem in the treatment of serious bacterial infections.
    Mohr JF
    Clin Infect Dis; 2008 Sep; 47 Suppl 1():S41-51. PubMed ID: 18713049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imipenem/cilastatin as initial single-agent therapy for infections in cancer patients with neutropenia.
    Fassas A; Papageorgiou T; Kontodimou A; Proya E; Hadjikyrkou M; Anagnostopoulos A
    J Chemother; 1989 Jul; 1(4 Suppl):1295-7. PubMed ID: 16312872
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy of teicoplanin and imipenem on respiratory infections in high risk patients.
    Piu G; Aresu G; Pautasso M; Garau G; Melis S; Ceccio S; Morini M; Palomba A
    J Chemother; 1991 Jan; 3 Suppl 1():222-3. PubMed ID: 12041770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imipenem/cilastatin with or without glycopeptide as initial antibiotic therapy for recipients of autologous stem cell transplantation: results of a Spanish multicenter study.
    de la Rubia J; Montesinos P; Martino R; Jarque I; Rovira M; Vázquez L; López J; Batlle M; de la Cámara R; Juliá A; Lahuerta JJ; Debén G; Díaz J; García R; Sanz MA
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):512-6. PubMed ID: 19285640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for ICU-acquired imipenem-resistant Gram-negative bacterial infections.
    Akinci E; Colpan A; Bodur H; Balaban N; Erbay A
    J Hosp Infect; 2005 Apr; 59(4):317-23. PubMed ID: 15749320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Febrile neutropenia in paediatric peripheral blood stem cell transplantation, in -vitro sensitivity data and clinical response to empirical antibiotic therapy.
    Ansari SH; Nasim S; Ahmed A; Irfan M; Ishaque A; Farzana T; Panjwani VK; Taj M; Shamsi TS
    J Coll Physicians Surg Pak; 2006 Nov; 16(11):704-8. PubMed ID: 17052420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emergence of imipenem resistance in clinical Escherichia coli during therapy.
    Oteo J; Delgado-Iribarren A; Vega D; Bautista V; Rodríguez MC; Velasco M; Saavedra JM; Pérez-Vázquez M; García-Cobos S; Martínez-Martínez L; Campos J
    Int J Antimicrob Agents; 2008 Dec; 32(6):534-7. PubMed ID: 18775649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.